Ageing

Ageing seems, at first glance, like something evolution should have eliminated. An organism that continues to function indefinitely would produce more offspring than one that deteriorates and dies. Natural selection favours traits that increase reproductive fitness. Why, then, does every known multicellular organism age?

The answer, developed across the second half of the 20th century by Peter Medawar, George Williams, and William Hamilton, is that natural selection's power to maintain function diminishes with age, because the probability of surviving to any given age in the wild decreases with time due to predation, disease, and accident. An allele that harms its carrier at age 70 is invisible to selection if most individuals in the ancestral population died by age 35. Selection cannot act on traits that are expressed after the organism has already reproduced and ceased to contribute to the gene pool.

Medawar formalised this insight in 1952 with the mutation accumulation theory: harmful mutations that are only expressed late in life accumulate in the genome because selection pressure against them is negligible. Williams extended this in 1957 with the theory of antagonistic pleiotropy: some genes may be actively beneficial in early life and harmful in late life, and selection maintains them because their early benefits outweigh their late costs. The classic proposed example is p53, the tumour suppressor protein, which prevents cancer by inducing cellular senescence or apoptosis in damaged cells but may contribute to ageing by progressively depleting stem cell populations through the same mechanism.

Thomas Kirkwood's disposable soma theory, proposed in 1977, provides a resource allocation framework: the organism faces a trade-off between investment in somatic maintenance and investment in reproduction. In environments where external mortality is high, selection favours high reproductive investment and low somatic maintenance, producing organisms that age quickly. In environments where external mortality is low, selection favours greater somatic investment, producing slower ageing. The theory predicts, and the data confirm, that species facing lower external mortality rates tend to live longer: bats, birds, and mole rats live far longer than their body size would predict for mammals, precisely because they face unusually low predation pressure.

The cellular and molecular changes that constitute ageing were systematically catalogued by Carlos Lopez-Otin and colleagues in a landmark 2013 review in Cell, which defined nine hallmarks of ageing: cellular and molecular changes that are universally present in aged organisms, that worsen with age, and that, when experimentally accelerated, hasten ageing, while ameliorating them extends healthspan or lifespan. A revised framework published in 2023 expanded this to twelve hallmarks.

Genomic instability is the accumulation of DNA damage over time, from oxidative damage, replication errors, and double-strand breaks, that the repair systems cannot fully keep pace with. Telomere attrition shortens chromosomes with each cell division until critical length triggers senescence or apoptosis. Epigenetic alterations drift the methylation and histone modification landscape progressively from the youthful pattern, measurable as epigenetic age by the Horvath clock.

Loss of proteostasis is the failure of the chaperone and degradation systems that clear misfolded proteins, principally the ubiquitin-proteasome system and autophagy. Both systems decline in efficiency with age. The accumulation of misfolded proteins is the molecular basis of many age-associated neurodegenerative diseases, including Alzheimer's disease (amyloid plaques and tau tangles), Parkinson's disease (alpha-synuclein aggregates), and Huntington's disease (huntingtin aggregates).

Deregulated nutrient sensing is the progressive dysregulation of the insulin/IGF-1 signalling pathway, the mTOR pathway, the AMPK pathway, and the sirtuin pathway, all of which integrate nutrient status with cellular maintenance and whose dysregulation is consistently associated with accelerated ageing. Mitochondrial dysfunction in aged cells shows reduced efficiency, higher reactive oxygen species production, and accumulated mutations in mitochondrial DNA.

Cellular senescence is the state in which a cell stops dividing and begins secreting a complex mixture of pro-inflammatory cytokines, proteases, and growth factors called the senescence-associated secretory phenotype (SASP). Senescent cells accumulate in aged tissues and create a chronic, low-grade inflammatory environment sometimes called inflammageing. Stem cell exhaustion reduces the regenerative capacity of essentially every tissue with age. Altered intercellular communication, principally through the SASP and changed circulating factors, creates a systemic shift in signalling that accelerates dysfunction across multiple tissues simultaneously.

The most reproducible intervention for extending lifespan in model organisms is caloric restriction (CR): reducing caloric intake by approximately 20 to 40 percent below ad libitum levels without malnutrition. Caloric restriction extends the lifespan of yeast, nematodes, fruit flies, mice, and rats, in many cases dramatically, and improves multiple healthspan measures across species.

The discovery that caloric restriction extended lifespan in rodents was first made by Clive McCay at Cornell University in 1935. The mechanism was unknown. The 60 years of research since have revealed the broad outlines of how caloric restriction signals through conserved nutrient-sensing pathways to slow the molecular processes that drive ageing.

Caloric restriction reduces the activity of mTOR (mechanistic target of rapamycin), a central coordinator of cell growth and metabolism that integrates signals from amino acids, growth factors, and energy status. Low mTOR activity promotes autophagy, reduces protein synthesis, and activates stress response pathways. Rapamycin, an inhibitor of mTOR, extends lifespan in mice even when administered late in life, one of the few pharmacological interventions to show robust lifespan extension in mammals.

Caloric restriction also activates the sirtuins, a family of NAD+-dependent deacetylases that regulate DNA repair, mitochondrial biogenesis, inflammatory gene expression, and metabolic regulation. Leonard Guarente at MIT identified in 1999 that the yeast sirtuin Sir2 was required for the lifespan extension produced by caloric restriction in yeast. The CALERIE trial, a randomised controlled trial of 25 percent caloric restriction in healthy humans over 2 years, showed beneficial effects on metabolic health, cardiovascular risk factors, and several ageing biomarkers, though lifespan outcomes in humans cannot be assessed in a trial of this duration.

Darren Baker and Jan van Deursen at the Mayo Clinic published in 2011 a landmark experiment in which a mouse model was engineered to allow senescent cells to be selectively eliminated by treatment with a drug. When senescent cells were cleared continuously from birth, the mice showed delayed onset of age-related phenotypes including cataracts, muscle wasting, and fat loss. When clearance was initiated in already-aged mice, the age-related phenotypes were partially reversed. The finding established that senescent cells are not merely passive bystanders in the ageing process but active contributors to tissue dysfunction.

The subsequent development of senolytics, small molecule drugs that selectively kill senescent cells by targeting the survival mechanisms that protect them from apoptosis, has progressed from mouse models into early human clinical trials. The combination of the drugs dasatinib and quercetin, the first senolytic combination to be tested clinically, has shown effects on senescent cell burden in human adipose tissue and has been trialled in patients with idiopathic pulmonary fibrosis, a condition strongly associated with senescent cell accumulation in lung tissue, with preliminary positive results.

The SASP is not only harmful in its chronic effects on surrounding tissue. It also plays roles in wound healing, tumour suppression, and embryonic development, which means that senolytics must be administered intermittently rather than continuously, to allow these beneficial functions to operate before the accumulating burden of senescent cells is periodically cleared. The optimal senolytic strategy remains an active area of investigation.

The genetic evidence for conserved longevity pathways is particularly compelling from work in the nematode Caenorhabditis elegans, a model organism of extraordinary value for ageing research precisely because its wild-type lifespan of approximately 3 weeks makes genetic screens for lifespan extension tractable.

Cynthia Kenyon at the University of California San Francisco discovered in 1993 that a single mutation in the gene daf-2, the C. elegans homologue of the insulin/IGF-1 receptor, doubled the lifespan of the worm. The extended lifespan required the activity of a downstream transcription factor, daf-16, which activated a programme of stress resistance, metabolic adjustment, and reduced protein synthesis. Kenyon's discovery launched a field: mutations reducing insulin/IGF-1 signalling have been shown to extend lifespan in multiple organisms across widely divergent taxa, suggesting deep evolutionary conservation of the relationship between nutrient sensing and lifespan.

In humans, studies of exceptionally long-lived individuals have identified genetic associations with variants in the insulin/IGF-1 signalling pathway and in the gene FOXO3, the human homologue of daf-16. ApoE genotype is among the most robustly replicated genetic associations with longevity in humans: the ApoE4 allele is associated with elevated Alzheimer's disease risk and reduced longevity, while the ApoE2 allele is associated with protection. The heritability of lifespan in humans is estimated at approximately 25 to 30 percent, with the remaining 70 to 75 percent reflecting non-genetic influences.

Rapamycin extends lifespan in mice, including when administration begins in animals equivalent in age to middle-aged humans, and improves immune function in elderly humans in a short-term trial. Its mechanism, inhibition of mTORC1 and consequent promotion of autophagy and reduction of protein synthesis, is directly relevant to multiple ageing hallmarks. The obstacles to its use as a longevity drug in humans are real: it is an immunosuppressant with documented side effects at therapeutic doses, and the dose-response relationship for longevity effects relative to immunosuppressive effects has not been established in humans.

Metformin, the most widely prescribed drug for type 2 diabetes, activates AMPK, a cellular energy sensor that coordinates responses to low energy availability in ways that overlap substantially with the effects of caloric restriction. Epidemiological data from multiple large cohorts show that diabetic patients taking metformin live longer than matched non-diabetic controls not taking metformin, a remarkable finding that suggests metformin's effects extend beyond glycaemic control to affect the rate of ageing-related processes more broadly. The TAME trial (Targeting Aging with Metformin), began enrolling participants in 2023. It is the first clinical trial in which ageing itself is designated as the target of intervention.

NAD+ precursors, principally nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), have attracted attention as potential longevity interventions because NAD+ levels decline with age and NAD+ is required for sirtuin activity, mitochondrial function, and DNA repair. Supplementation with NMN or NR raises NAD+ levels in rodents and humans and improves various metabolic parameters in aged mice. Whether NAD+ supplementation affects the rate of human ageing in any clinically meaningful sense is not established.

One of the more striking experimental findings in ageing biology involves parabiosis: the surgical joining of the circulatory systems of two animals, such that they share a bloodstream. When old mice are joined to young mice, the old mice show improvements in multiple age-related measures: improved muscle regeneration, enhanced cognitive function, increased neurogenesis in the hippocampus, and reversal of some cardiac hypertrophy. The implication is that factors circulating in young blood rejuvenate old tissues, and conversely that factors in old blood impair young tissue function.

Amy Wagers and colleagues at Harvard identified GDF11 (growth differentiation factor 11) as a circulating factor that declines with age and whose systemic administration improves cardiac and skeletal muscle function in aged mice. Subsequent work contested whether GDF11 actually declines with age and whether the cardiac effects were real, producing a controversy that illustrated the difficulty of parabiosis research. More recently, Saul Villeda and colleagues at UCSF identified that the protein TIMP2, present in cord blood, improves hippocampal function in aged mice, and that old plasma contains elevated levels of beta2-microglobulin and CCL11, factors that appear to impair neurogenesis and cognitive function.

The clinical translation of parabiosis research into human interventions remains highly speculative and ethically contested. Young blood plasma transfusion services have operated in the United States offering infusions of young donor plasma to paying customers, without any established evidence of efficacy and without the oversight of a clinical trial. The FDA has specifically warned against these services. What parabiosis research does establish is that ageing is not solely a cell-autonomous process: the systemic environment shapes the ageing rate of individual tissues, and modifying that environment can, in animal models, reverse some age-related changes.

The brain ages differently from other organs, in ways that are both more consequential and less well understood. Unlike most other tissues, the brain has minimal regenerative capacity in adulthood. Most of the neurons present at birth are present for life. Their loss is irreplaceable.

Structural brain ageing is measurable from early adulthood. Cortical grey matter volume decreases at a rate of approximately 0.2 percent per year from early adulthood, accelerating after age 60. White matter integrity declines with age, slowing information transfer between regions. The hippocampus, critical for the formation of new memories, shows among the most pronounced age-related volume loss of any brain structure, and the rate of hippocampal volume loss correlates with cognitive decline.

Alzheimer's disease affects approximately 50 million people worldwide and is the most common form of dementia. Its pathological hallmarks are the extracellular accumulation of amyloid beta peptide into plaques and the intracellular accumulation of hyperphosphorylated tau protein into neurofibrillary tangles. The amyloid hypothesis, which holds that amyloid accumulation is the initiating event in the disease cascade, has been the dominant framework for Alzheimer's research and drug development for decades, producing a sequence of failed clinical trials. The approval of the anti-amyloid antibody lecanemab in 2023 provided the first evidence that reducing amyloid burden slows the rate of cognitive decline, though the effect size was modest and the clinical significance debated.

The populations with the highest concentrations of centenarians and supercentenarians in the world have been identified and studied in a research programme partly popularised by journalist Dan Buettner under the name Blue Zones. The five original Blue Zones were Sardinia in Italy, Okinawa in Japan, Loma Linda in California, Nicoya Peninsula in Costa Rica, and Ikaria in Greece. Each region showed substantially elevated proportions of individuals living past 100 compared to national averages.

The shared characteristics of Blue Zone populations have been described as low smoking rates, high physical activity integrated into daily life, plant-rich diets with moderate caloric intake and low consumption of processed foods, strong social connection and sense of purpose, and moderate alcohol consumption in some but not all populations. These characteristics map onto the same pathways that caloric restriction, exercise, and low chronic inflammation modulate in model organisms.

Saul Newman at the Australian National University published an analysis in 2019 showing that within the United States, counties with the highest density of centenarians are statistically associated with indicators of poor vital registration quality. The Blue Zone findings may be partly, though not entirely, a data quality artefact. The lifestyle factors identified remain plausible contributors to longevity even if the extreme longevity claims require further verification.

The most radical hypothesis in current longevity research holds that ageing is primarily an epigenetic process: that the molecular changes that constitute ageing are information losses in the epigenome that are, in principle, reversible by restoring the epigenetic state of aged cells to a younger pattern. This is the information theory of ageing as developed by David Sinclair at Harvard.

The experimental foundation comes from studies of partial reprogramming: exposing aged cells or tissues to the Yamanaka factors used to generate iPSCs, but for a limited period insufficient to fully reprogram the cells back to pluripotency, is sufficient to reverse many age-related epigenetic changes and restore a younger functional state. In a 2020 study from Sinclair's laboratory, partial reprogramming of retinal ganglion cells in aged mice using three of the four Yamanaka factors reversed epigenetic age as measured by the Horvath clock and restored vision in mice with age-related visual decline. Subsequent studies from multiple groups have shown partial reprogramming effects in muscle, skin, and the whole body of mice transiently exposed to Yamanaka factor expression.

The limitations and uncertainties are significant. The Yamanaka factors include c-Myc, a proto-oncogene whose inappropriate activation can drive cancer. Reprogramming strategies that exclude c-Myc are safer but less efficient. The relationship between epigenetic clock reversal and genuine biological rejuvenation requires careful validation for each tissue and each endpoint. And the translation from mouse to human involves the scale challenges that attend all mouse ageing research: a mouse that ages over 2 to 3 years is a fundamentally different system from a human that ages over 80 to 90 years.

Ageing is a strange property for a biological system to have. Life is, at the most fundamental level, defined by the capacity to maintain organisation against entropy, to repair damage, to reproduce, and to persist. Ageing is the failure of these capacities over time. It seems to contradict what life is.

The evolutionary account resolves the paradox. Ageing is not life failing. It is life doing precisely what evolution shaped it to do: investing enough in somatic maintenance to reproduce successfully in an environment with certain levels of external mortality, and no more. The organism is not being worn down by time. It is being maintained to a specification set by the selection pressures of its evolutionary history, a specification that is now, in the radically altered mortality environment of modern humans, producing a mismatch between the system's evolved maintenance allocation and the extended lifespan that reduced external mortality makes possible.

What that intervention ultimately means, not just biologically but for the organisation of human societies, for the meaning of mortality, for the allocation of resources across generations, are questions that the biology does not answer but that the biology makes urgent. The 37 trillion cells of the human body were maintained with sufficient fidelity to allow the reader to exist. The question that ageing biology now asks is how much longer that fidelity could, in principle, be sustained, and what it would cost and mean to sustain it.